SINGapore SoniCracker IntraVascular Lithotripsy (SING IVL) Study

ConditionCardiovascular Diseases

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age21+

SponsorNational Heart Centre Singapore

About this trial

Interventional cardiologists are facing an increasing burden of calcified coronary arteries in keeping with an ageing population and rising prevalence of diabetes mellitus and chronic kidney disease. Heavily calcified plaques impede balloon dilatation and successful stent delivery, resulting stent under-expansion, malposition, and damage to the drug-eluting polymer coats. This translates to poorer procedural outcomes and increased risk of Major Adverse Cardiovascular Events (MACE). The investigators' proposal seeks to determine the feasibility of the SoniCracker IVL in patients with calcified coronary lesions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients at age ≥ 21 years old.

Patients undergoing elective/ planned PCI with at least moderate coronary calcification on angiography at the target lesion are eligible for enrolment. Moderate coronary calcification is defined as densities on only one side of the arterial wall prior to contrast injection. Severe calcification was defined as radiopacities on both sides of the arterial wall prior to contrast injection.

Patients need to demonstrate evidence of either a 180 arc of coronary calcium or nodular calcium at the target lesion on intravascular imaging prior to IVL therapy.

Disqualifiers

Cardiac arrest

Cardiogenic shock

Collapse / comatose / semi-conscious states

Patients requiring urgent or emergent PCI.

Trial design

Design model

Single group

Treatments tested in this trial

Medical device
Device
The SoniCracker IVL is a rapid-exchange catheter with an effective length of 1420mm, with two radiopaque markers at the distal end and is coated with a hydrophilic coating from the distal tip to the wire exchange port to facilitate tracking and catheter delivery during use. The catheter lumen consists of a wire lumen, an inflation lumen, and two shockwave electrodes. The wire lumen allows passage of a 0.014" guidewire to guide the catheter into and through the lesion. The inflation lumen is filled with a 50%/50% mixture of physiological saline and contrast media to inflate and deflate the balloon. The electrode traverses the entire effective length of the catheter for lithotripsy treatment. The proximal end of the catheter features a hub with two ports, one for inflation/deflation of the balloon, and the other for connecting the electrode wires to the Coronary intravascular lithotripsy therapy device.

Treatment groups

40 Participants

are divided into 1 treatment group

Group A: SoniCracker IVLExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Procedural success

Successful delivery and deployment of the study device, and attainment of less than 50% diameter stenosis after stenting with no evidence of in-hospital major adverse cardiac events (MACE: cardiac death, myocardial infarction or target vessel revascularization)

Time frame

Perioperative

Secondary outcomes

Device success (successful delivery and deployment of a device, and attainment of less than 50% diameter stenosis), 30-day MACE, coronary complications, post procedural angiographic and intravascular imaging outcomes

Time frame

Up to 30 days (+ 1 month) post PCI

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Heart Centre Singapore

Lead sponsor

Biosensor Interventional Technologies Pte Ltd

Collaborator

Source ClinicalTrials.gov

Apply now